NCT03576755

Spironolactone Therapy In Young Women With NASH

17 people

100%

17 womenmiddle line = equal numbers0 men

Phase: PHASE1, PHASE2
Paid for by: University of California, San Francisco
Finished: 2023-07-05
Health conditions: NASH - Nonalcoholic Steatohepatitis
Who could join: Women only
Ages: 18 Years – 45 Years
Average age: mean 32 Years
Age 65+: 0%
Weight (BMI): Not reported
Pregnancy recorded: Not reported
Menopause recorded: Not reported
Results shown by sex: Not split by sex
Race: White 82.4% · Asian 17.6% · American Indian / Alaska Native 0% · Native Hawaiian / Pacific Islander 0% · Black / African American 0% · More than one race 0% · Not reported 0%

Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 45 Years.”
No pregnant women
Women who were pregnant could not join.
“Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study”
No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study”
Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study”
No kidney or liver problems
Women with kidney or liver problems were turned away.
“Other forms of chronic liver disease including hepatitis B virus infection (hepatitis B surface antigen positive), chronic hepatitis C virus (HCV) infection (HCV Ab and HCV ribonucleic acid positive), autoimmune disorders (e.g., primary bil…”
No diabetes
Women with diabetes were turned away.
“Uncontrolled diabetes (HbA1c 9.5% or higher within 60 days prior to enrollment)”

Study titles and rules are shown in their original English.